Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer
Masako Nakamura(Shiga University of Medical Science), Yataro Daigo(The University of Tokyo), Bayarbat Tsevegjav(Shiga University of Medical Science), Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), Phung Manh Thang(Shiga University of Medical Science), Yohei Miyagi(Kanagawa Cancer Center), Ming Zhu(AbbVie (United States)), Atsushi Takano(The University of Tokyo), Tomoyuki Yokose(Kanagawa Prefectural Hospital Organization)
Cited by 61
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
|Nature Genetics|2000|950
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752